Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656
In early March, Ambry Genetics (Aliso Viejo, Calif.) reached the milestone of having
sequenced 10,000 clinical diagnostic samples with next-generation sequencing (NGS)
and processed 100,000 total NGS samples. Ambry has a proud history of being on the
forefront of genetic testing, having been among the first purchasers of commercially
available sequencing instruments back in 2007. The company says it was the first to offer
an NGS-based diagnostic test in April 2010, with the introduction of its 81-gene panel
for X-linked intellectual disability. Ambry continued with its list of firsts by launching
the first clinically available whole-exome sequencing test at a CLIA-certified laboratory
in 2011.
Evolving from its roots in cystic fibrosis (CF) testing, Ambry continues to develop and
enhance its comprehensive testing menu with significant investments in automation.
This has allowed the company to focus on reducing test turnaround time while retaining
its focus on quality client service and steadfast attention to their guiding ethical
principles. Recently, Ambry CEO Charles Dunlop spoke to DTTR about the evolution of NGS in
clinical care and Ambry’s commitment to rapid, yet responsible, growth in the future.
Ambry Genetics, a subsidiary of REALM IDx, Inc., translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.
Media Contact
Mickie Henshall
Chief Marketing Officer
REALM IDx
mhenshall@realmidx.com